Skip to main content

Clinical trial B1931030

A phase 4, open label, randomized study of two Inotuzumab Ozogamicin dose levels in adult patients with relapsed or refractory b cell acute lymphoblastic leukemia eligible for hematopoietic stem cell transplantation and who have risk factor(s) for veno occlusive disease

Organ Acute leukemia
Trial status Trial closed
Trial type
Interventional with experimental drug
Phase Trial phase 4
Academic trial Non
Sponsor Pfizer
EudraCT Identifier 2018-001557-27
Inclusion criteria Relapsed or refractory precursor CD22-positive B-cell ALL and who are eligible for HSCT - Have 1 or more of the following risk factors for developing VOD: a. Due to receive Salvage 2 or greater; b. Prior HSCT;c. Age >=55 years
Last update